Orbimed Advisors LLC Prelude Therapeutics Inc Call Options Transaction History
Orbimed Advisors LLC
- $4.44 Billion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding PRLD
# of Institutions
59Shares Held
34.2MCall Options Held
200Put Options Held
0-
Baker Bros. Advisors LP New York, NY10.1MShares$34.9 Million0.61% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4.13MShares$14.3 Million0.4% of portfolio
-
Boxer Capital, LLC San Diego, CA2.57MShares$8.86 Million0.63% of portfolio
-
Black Rock Inc. New York, NY1.1MShares$3.79 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.02MShares$3.51 Million0.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $125M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...